A1 adenosine receptor antagonists

Details A1 adenosine receptor antagonists A1 adenosine receptor antagonists

2006-04-04

2006-04-04

Henley, III, Raymond J. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

07022710

ABSTRACT:
Disclosed are novel methods of antagonizing the A1adenosine receptor in a mammal, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of the formula:wherein R1is optionally substituted C1-14alkyl; Y is C1-14alkylene; and Z is phenyl that is optionally substituted with halo, hydroxy, amino, cyano, or optionally substituted C1-4alkyl or a pharmaceutically acceptable salt, ester, or prodrug thereof. The A1adenosine receptors are antagonized in order to treat a disease state is chosen from renal failure, renal dysfunction, nephritis, hypertension, edema, Alzheimers disease, stress, depression, cardiac arrhythmia, restoration of cardiac function, congestive heart failure, diabetes, asthma, respiratory disorders, ischemia-induced injury of the brain, heart and kidney, and diarrhea.

REFERENCES:
patent: 6770651 (2004-08-01), Palle et al.
patent: 2003/0050272 (2003-03-01), Palle et al.
patent: 2004/0209899 (2004-10-01), Palle et al.
patent: WO 00/73307 (2000-12-01), None
patent: WO 01/16134 (2001-03-01), None

Affiliated with

Also associated with

Rating

A1 adenosine receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with A1 adenosine receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and A1 adenosine receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3566324